Trial | NCT01184599  Report issue

Title

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    aliskiren ...

  • Study Participants

    30
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
Study Started
Jun 30
2010
Primary Completion
Mar 31
2013
Anticipated
Last Update
Jun 27
2011
Estimate

Drug aliskiren

150 mg/day p.o.

Criteria 

Inclusion Criteria:

IgA nephropathy confirmed by renal biopsy
Hypertension (<= 125/75 mmHg)

Exclusion Criteria:

Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks
Severe hypertension (<= 180/110 mmHg) or secondary hypertension
Patients with history of allergy or adverse effect for aliskiren
Renal dysfunction (estimated Glomerular Filtration Rate < 60 mL/min/1.73m2)
Pregnancy
Patient treated with cyclosporine
Hyperkalemia (serum potassium >= 5.6 mmol/L)
Autoimmune disease including systemic lupus erythematosus
Patients inadequate for the study
No Results Posted